Gsa Capital Partners LLP Intercept Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$11.23 - $19.59 $193,807 - $338,084	-17,258 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$13.37 - $17.79 $63,868 - $84,982	-4,777 Reduced 21.68%	17,258 $281,000
Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $815,530 - $1.12 Million	-57,110 Reduced 72.16%	22,035 $359,000
Q3 2021 Nov 12, 2021	BUY	$12.99 - $20.47 $1.03 Million - $1.62 Million	79,145 New	79,145 $1.18 Million
Q4 2019 Feb 12, 2020	SELL	$57.36 - $124.1 $412,934 - $893,395	-7,199 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$58.69 - $80.46 $422,509 - $579,231	7,199 New	7,199 $478,000
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $733,087 - $916,484	-12,596 Closed	0 $0
Q3 2017 Nov 20, 2017	BUY	$57.01 - $118.75 $718,097 - $1.5 Million	12,596	12,596 $731,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.